Year |
Citation |
Score |
2023 |
Wang Z, Li W, Jiang Y, Tran TB, Cordova LE, Chung J, Kim M, Wondrak G, Erdrich J, Lu J. Sphingomyelin-derived nanovesicles for the delivery of the IDO1 inhibitor epacadostat enhance metastatic and post-surgical melanoma immunotherapy. Nature Communications. 14: 7235. PMID 37945606 DOI: 10.1038/s41467-023-43079-4 |
0.715 |
|
2023 |
Wang Z, Gonzalez KM, Cordova LE, Lu J. Nanotechnology-empowered therapeutics targeting neurodegenerative diseases. Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology. e1907. PMID 37248794 DOI: 10.1002/wnan.1907 |
0.576 |
|
2023 |
Jiang T, Gonzalez KM, Cordova LE, Lu J. Nanotechnology-enabled gene delivery for cancer and other genetic diseases. Expert Opinion On Drug Delivery. 1-18. PMID 37017558 DOI: 10.1080/17425247.2023.2200246 |
0.3 |
|
2023 |
Li W, Jiang Y, Lu J. Nanotechnology-enabled immunogenic cell death for improved cancer immunotherapy. International Journal of Pharmaceutics. 122655. PMID 36720448 DOI: 10.1016/j.ijpharm.2023.122655 |
0.737 |
|
2022 |
Wang Z, Cordova LE, Chalasani P, Lu J. Camptothesome Potentiates PD-L1 Immune Checkpoint Blockade for Improved Metastatic Triple-Negative Breast Cancer Immunochemotherapy. Molecular Pharmaceutics. 19: 4665-4674. PMID 36413426 DOI: 10.1021/acs.molpharmaceut.2c00701 |
0.632 |
|
2022 |
Li W, Gonzalez KM, Chung J, Kim M, Lu J. Surface-modified nanotherapeutics targeting atherosclerosis. Biomaterials Science. PMID 35980230 DOI: 10.1039/d2bm00660j |
0.683 |
|
2022 |
Wang Z, Li W, Park J, Gonzalez KM, Scott AJ, Lu J. Camptothesome elicits immunogenic cell death to boost colorectal cancer immune checkpoint blockade. Journal of Controlled Release : Official Journal of the Controlled Release Society. 349: 929-939. PMID 35926754 DOI: 10.1016/j.jconrel.2022.07.042 |
0.725 |
|
2021 |
Wang Z, Little N, Chen J, Lambesis KT, Le KT, Han W, Scott AJ, Lu J. Immunogenic camptothesome nanovesicles comprising sphingomyelin-derived camptothecin bilayers for safe and synergistic cancer immunochemotherapy. Nature Nanotechnology. PMID 34385682 DOI: 10.1038/s41565-021-00950-z |
0.717 |
|
2021 |
Li W, Little N, Park J, Foster CA, Chen J, Lu J. Tumor-Associated Fibroblast-Targeting Nanoparticles for Enhancing Solid Tumor Therapy: Progress and Challenges. Molecular Pharmaceutics. PMID 34260250 DOI: 10.1021/acs.molpharmaceut.1c00455 |
0.717 |
|
2020 |
Wang Z, Chen J, Little N, Lu J. Self-assembling Prodrug Nanotherapeutics for Synergistic Tumor Targeted Drug Delivery. Acta Biomaterialia. PMID 32454086 DOI: 10.1016/J.Actbio.2020.05.026 |
0.721 |
|
2018 |
Liu X, Jiang J, Chan R, Ji Y, Lu J, Liao YP, Okene M, Lin J, Lin P, Chang CH, Wang X, Tang I, Zheng E, Qiu W, Wainberg ZA, et al. Improved Efficacy and Reduced Toxicity Using a Custom-Designed Irinotecan-Delivering Silicasome for Orthotopic Colon Cancer. Acs Nano. PMID 30525443 DOI: 10.1021/Acsnano.8B06164 |
0.409 |
|
2017 |
Liu X, Jiang J, Ji Y, Lu J, Chan R, Meng H. Targeted drug delivery using iRGD peptide for solid cancer treatment. Molecular Systems Design & Engineering. 2: 370-379. PMID 30498580 DOI: 10.1039/C7ME00050B |
0.457 |
|
2017 |
Lu J, Liu X, Liao YP, Salazar F, Sun B, Jiang W, Chang CH, Jiang J, Wang X, Wu AM, Meng H, Nel AE. Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression. Nature Communications. 8: 1811. PMID 29180759 DOI: 10.1038/S41467-017-01651-9 |
0.452 |
|
2015 |
He C, Lu J, Lin W. Hybrid nanoparticles for combination therapy of cancer. Journal of Controlled Release : Official Journal of the Controlled Release Society. PMID 26387745 DOI: 10.1016/J.Jconrel.2015.09.029 |
0.449 |
|
2015 |
Lu J, Liu C, Wang P, Ghazwani M, Xu J, Huang Y, Ma X, Zhang P, Li S. The self-assembling camptothecin-tocopherol prodrug: An effective approach for formulating camptothecin. Biomaterials. 62: 176-87. PMID 26057133 DOI: 10.1016/J.Biomaterials.2015.05.046 |
0.43 |
|
2014 |
Lu J, Zhao W, Liu H, Marquez R, Huang Y, Zhang Y, Li J, Xie W, Venkataramanan R, Xu L, Li S. An improved D-α-tocopherol-based nanocarrier for targeted delivery of doxorubicin with reversal of multidrug resistance. Journal of Controlled Release : Official Journal of the Controlled Release Society. 196: 272-86. PMID 25456831 DOI: 10.1016/J.Jconrel.2014.10.016 |
0.479 |
|
2014 |
Zhang X, Huang Y, Zhao W, Liu H, Marquez R, Lu J, Zhang P, Zhang Y, Li J, Gao X, Venkataramanan R, Xu L, Li S. Targeted delivery of anticancer agents via a dual function nanocarrier with an interfacial drug-interactive motif. Biomacromolecules. 15: 4326-35. PMID 25325795 DOI: 10.1021/Bm501339J |
0.452 |
|
2014 |
Lu J, Zhao W, Huang Y, Liu H, Marquez R, Gibbs RB, Li J, Venkataramanan R, Xu L, Li S, Li S. Targeted delivery of Doxorubicin by folic acid-decorated dual functional nanocarrier. Molecular Pharmaceutics. 11: 4164-78. PMID 25265550 DOI: 10.1021/Mp500389V |
0.526 |
|
2014 |
Zhang Y, Huang Y, Zhao W, Lu J, Zhang P, Zhang X, Li J, Gao X, Venkataramanan R, Li S. Fmoc-conjugated PEG-vitamin E2 micelles for tumor-targeted delivery of paclitaxel: enhanced drug-carrier interaction and loading capacity. The Aaps Journal. 16: 1282-91. PMID 25193267 DOI: 10.1208/S12248-014-9651-2 |
0.45 |
|
2014 |
Zhang P, Huang Y, Liu H, Marquez RT, Lu J, Zhao W, Zhang X, Gao X, Li J, Venkataramanan R, Xu L, Li S. A PEG-Fmoc conjugate as a nanocarrier for paclitaxel. Biomaterials. 35: 7146-56. PMID 24856103 DOI: 10.1016/J.Biomaterials.2014.04.108 |
0.446 |
|
2014 |
Chen Y, Zhang X, Lu J, Huang Y, Li J, Li S. Targeted delivery of curcumin to tumors via PEG-derivatized FTS-based micellar system. The Aaps Journal. 16: 600-8. PMID 24706375 DOI: 10.1208/S12248-014-9595-6 |
0.513 |
|
2014 |
Zhang P, Lu J, Huang Y, Zhao W, Zhang Y, Zhang X, Li J, Venkataramanan R, Gao X, Li S. Design and evaluation of a PEGylated lipopeptide equipped with drug-interactive motifs as an improved drug carrier. The Aaps Journal. 16: 114-24. PMID 24281690 DOI: 10.1208/S12248-013-9536-9 |
0.44 |
|
2013 |
Lu J, Huang Y, Zhao W, Chen Y, Li J, Gao X, Venkataramanan R, Li S. Design and characterization of PEG-derivatized vitamin E as a nanomicellar formulation for delivery of paclitaxel. Molecular Pharmaceutics. 10: 2880-90. PMID 23768151 DOI: 10.1021/Mp300729Y |
0.376 |
|
2013 |
Zhang X, Lu J, Huang Y, Zhao W, Chen Y, Li J, Gao X, Venkataramanan R, Sun M, Stolz DB, Zhang L, Li S. PEG-farnesylthiosalicylate conjugate as a nanomicellar carrier for delivery of paclitaxel. Bioconjugate Chemistry. 24: 464-72. PMID 23425093 DOI: 10.1021/Bc300608H |
0.429 |
|
2013 |
Gao X, Huang Y, Makhov AM, Epperly M, Lu J, Grab S, Zhang P, Rohan L, Xie XQ, Wipf P, Greenberger J, Li S. Nanoassembly of surfactants with interfacial drug-interactive motifs as tailor-designed drug carriers. Molecular Pharmaceutics. 10: 187-98. PMID 23244299 DOI: 10.1021/Mp300319M |
0.399 |
|
2013 |
Lu J, Huang Y, Zhao W, Marquez RT, Meng X, Li J, Gao X, Venkataramanan R, Wang Z, Li S. PEG-derivatized embelin as a nanomicellar carrier for delivery of paclitaxel to breast and prostate cancers. Biomaterials. 34: 1591-600. PMID 23182923 DOI: 10.1016/J.Biomaterials.2012.10.073 |
0.406 |
|
2012 |
Huang Y, Lu J, Gao X, Li J, Zhao W, Sun M, Stolz DB, Venkataramanan R, Rohan LC, Li S. PEG-derivatized embelin as a dual functional carrier for the delivery of paclitaxel. Bioconjugate Chemistry. 23: 1443-51. PMID 22681537 DOI: 10.1021/Bc3000468 |
0.442 |
|
Show low-probability matches. |